Kornimate/medical-research-clean huggingface dataset:
early motion total ankle artroplasty

Conditions: Ankle Osteoarthritis; Ankle - Recurrent Dislocation; Cartilage Disease; Ankle Arthropathy

Summary: evaluate the clinical and radiographic results of patients undergoing total ankle arthroplasty and treated in the post-operative period in a randomized manner with early mobilization of the ankle joint or with cast immobilization for 3 weeks


Eligibility criteria:
inclusion criteria: * adult patients (aged between 18 and 80). * male or female patients; * signature of the informed consent for participation in the study; * patients prepared and motivated to comply with the scheduled follow-up visits and the completion of the study questionnaires exclusion criteria: * main diagnosis other than osteoarthritis, history of ankle infection * need to carry out surgical interventions associated with total prosthesis ankle (e.g., calcaneal osteotomy, knee lowering osteotomy). first metatarsal bone, supramalleolar osteotomy, etc.) * intraoperative complications (for example a malleolar fracture) which require a different post-operative protocol * peripheral vascular disease * marked osteoporosis of the ankle and foot * osteonecrosis of the talus * neurological disorders affecting the lower limb inability to understand study information or respond to questionnaires due to cognitive or linguistic deficits * patients who are pregnant or breastfeeding
anti-1-amino-3-[18f]fluorocyclobutyl-1-carboxylic acid (anti-[18f](facbc)positron emission tomography (pet-ct) of the breast

Conditions: Breast Cancer

Summary: breast carcinoma is the most frequent cancer in women, affecting an estimated 207,090 in 2010 leading to 39,840 cancer related deaths. fludeoxyglucose f 18 injection (fdg) positron emission tomography, (pet) or pet-ct has become the a standard method for isolating the tumor. however, fdg is insensitive in small breast tumors and certain histologic types such as lobular, certain types of breast carcinoma. in addition, fdg uptake can be nonspecific since inflammatory some benign lesions may also evidence have accumulation of this radiotracer. hence there is a need for a tracer/imaging tool that increases the ability to characterize detect breast carcinoma and to detect locoregional spread, as well as monitor therapeutic treatment response. anti-3-\[18f\]. anti-1-amino-3-\[18f\]fluorocyclobutyl-1-carboxylic acid (facbc) is an amino acid based pet radiotracer which has shown utility in detecting a variety of tumors. in cell culture experiments,facbc has shown uptake in the breast tumor cell line. the primary aim of this study is to determine if facbc pet-ct demonstrates uptake within breast carcinoma (primary site and/or locoregional lymph nodes) and to study uptake kinetics via time-activity curves from dynamic imaging characteristics. the investigators will enroll 12 patients who have a breast mass or masses and/or lymph nodes naïve to therapy about to undergo biopsy or post-biopsy pre-therapy. all patients will undergo standard of care imaging as appropriate such as mammography, ultrasound, mr, and/or fdg pet-ct scanning. the investigators will then compare findings to determine if this radiotracer is worthy of further study in a more comprehensive experiment.


Eligibility criteria:
inclusion criteria: 1. patients must be 18 years of age or older. 2. patients will have a breast mass and/or lymph nodes naïve to therapy about to undergo biopsy or post-biopsy pre-therapy. patients with known or suspected recurrent disease will be eligible for this protocol. 3. ability to lie still for pet scanning 4. patients must be able to provide written informed consent exclusion criteria: 1. age less than 18. 2. inability to lie still for pet scanning. 3. cannot provide written informed consent. 4. current therapy for breast carcinoma. 5. positive serum or urine pregnancy test within 24 hours of study.
analysis of joint sounds in the diagnosis of knee disorders

Conditions: Arthritis of Knee; Normal Knee; Knee Arthroscopy

Summary: clinical-noninvasive recording of sounds from the knees through a brief loaded range of motion. description in phase 1 analytic but descriptive as well in phase 2. no samples other than a sound recording. the device is known microphone attached to the skin of the knee with elastic material. sound recorded and analyzed on a lap top computer with adobe software.

there is a need for a less expensive and more universally available screening device for the knee, and other joint pathology. the equipment used for ultrasound is much less expensive and cumbersome than that of an x-ray or magnetic resonance imaging. the equipment we will use for the analysis of sound produced by the body itself is an order of magnitude less expensive than ultrasound; such as a laptop computer with currently available software and an inexpensive transducer. analysis of sound has proved useful in pulmonology and cardiology. we believe sound analysis will provide a useful yet inexpensive tool for primary care physicians as well as musculoskeletal specialists. phase 1: establish the normal sound patterns emanating from the uninjured knee; we will look for the influence of age, height and weight. phase 2: to record and analyze the preoperative sound patterns from the knees with pathology, known by mri and arthroscopy, then compare them with the normal sounds from phase 1.

Eligibility criteria:
inclusion criteria: phase i * healthy individuals. * no neurological problems. * no knee complaints. * no previous surgery or knee injuries. phase ii patients undergoing knee arthroscopy who have pre-op mri. the inclusion will be based on age group, 20 years of age, 40 and 60. exclusion criteria: * neurologic disease * previous serious injury (fracture or dislocation). * previous ligament reconstruction. * major non-subtitle problems with their knees. (this would create overwhelming noises).

Keywords: knee healthy arthroscopy mri amplification sounds pre-operative analyzing
acceptance and commitment therapy in the treatment of obesity: pilot.

Conditions: Obesity, Acceptance and Commitment Therapy, Weight Management Service

Summary: obesity is an 'epidemic' within the uk. individuals living with obseity are at risk of developing cancer, heart problems and dieing. furthermore, obesity impacts on psychological wellbeing via lowered self-efficacy, self-esteem, body image and overall quality of life (qol). a pilot randomised controlled trial (rct) is proposed to investigate the additional benefit of a psychological intervention alongside treatment as usual (tau) in a weight management service. patients routinely attending an outpatient clinic will be randomised into tau with or without additional acceptance and commitment therapy (act) group based-input and their outcomes monitored over time.

overweight and obesity is reported as an 'epidemic' problem within the uk as well as the world. individuals living with this may be at higher risk of developing co-morbidities, such as cancers, heart problems or diabetes, and higher mortality rates are reported in this group. furthermore, overweight and obesity can also impact on a person's psychological wellbeing, such as their self-efficacy, self-esteem and body image as well as have a negative effect on their overall quality of life (qol). therefore, a pilot randomised controlled trial (rct) is proposed to investigate the additional benefit of a psychological intervention alongside treatment as usual (tau) in a weight management service. patients routinely attending an outpatient clinic will be randomised into tau with or without additional acceptance and commitment therapy (act) group based-input.

Eligibility criteria:
inclusion criteria: * individuals will be willing and able to give informed consent for participation in the study; * male or female, aged 18 years or above. * individuals will have a body mass index (bmi) of over 40 (or over 35 if they are from a black or other minority ethic (bme) group or have a co-existing physical health problem); * individuals will be on a waiting list for a weight loss management programme in the uk; * individuals will have english as a written language. exclusion criteria: * individuals who are currently pregnant or breastfeeding; * individuals with current drug or alcohol abuse, such that would prevent them from engaging in a weight management programme; * individuals who are acutely mentally unwell, such that would prevent them from engaging in a weight management programme; * individuals who at time of referral are at significant risk to themselves of others, such that would prevent them from engaging in a weight management programme; * individuals who are acutely physically unwell and/or hospitalised, such that would prevent them from engaging in a weight management programme; * individuals who have a learning disability or cognitive impairment, such that would prevent them from engaging in a weight management programme. * currently in receipt of psychiatric services.
effects of tribulus terrestris on sexual function in post-menopausal women

Conditions: Sexual Functions and Problems in the Adult

Summary: objective: to study the effects of tribulus terrestris on sexuality in postmenopausal women.

sexuality is an integral part of every personality, influence thoughts, feelings, actions, integrations, and therefore the physical and mental health. it is estimated that 43% of women have at least one complaint of sexual problem. disorders of desire and arousal are among the most common problems found in gynecologic practice. medicinal plants have been used for therapeutic purposes for thousands of years, and aphrodisiac properties described in several plants. tribulus terrestris is a plant indigenous to india, recommended in the treatment of infertility, low libido and impotence, and its main active ingredient protodioscin (ptn).

Eligibility criteria:
inclusion criteria: * women past menopause, with full autonomy, at least one year of amenorrhea and fsh\> 30 miu / ml. * sexually active * partner is stable and without sexual difficulties * carrier sexual abuse (desire, arousal, orgasm and dyspareunia) exclusion criteria: * women on hormone therapy within the preceding 12 months * women without sexual activity * with diabetes mellitus * patients with cognitive impairment * patients with hormone-dependent tumor * history of psychiatric illness * patients with liver disease * patients with kidney disease * users of drugs with proven to decrease sexual desire * cardivascular disease, renal disease.

Keywords: menopause sexual dysfunction tribulus sexuality phytotherapeutic drugs
growth hormone and insulin growth factor 1 deficiencies in children/adolescents following traumatic brain injury: the impact on growth and neuropsychological development

Conditions: Traumatic Brain Injury

Summary: the purpose of this study is to look at the relationship between growth hormones, and recovery from a tbi - traumatic brain injury. it is believed that a tbi may interfere with the body's ability to produce growth hormones. these hormones may be needed by the body for growth, mental development and sexual maturation.


Eligibility criteria:
inclusion criteria: * this is phase ii trial-subjects have already completed phase i. * traumatic brain injury (tbi). * results of the blood work from phase i shows that your growth hormone levels are low. exclusion criteria: * have not completed phase i of the study.

Keywords: growth hormone replacement subject 8 to 21 moderate to severe traumatic brain injury growth hormone deficient
prophylactic plasma infusion therapy for congenital thrombotic thrombocytopenic purpura

Conditions: Purpura, Thrombotic Thrombocytopenic

Summary: congenital thrombotic thrombocytopenic purpura (ttp), also called upshaw-schulman syndrome or hereditary or familial ttp is a rare, but severe disease. the purpose of this study is to determine how infusions of plasma to patients with congenital ttp correlate with symptoms and signs of activity of the disease, and to determine why some patients need more frequent infusions of plasma than others to prevent acute attacks of the disease.

patients with congenital ttp have an inherited lack of function or amount of a protein in plasma called adamts13, that otherwise is responsible for cleaving large von willebrand-molecules into smaller parts. the patients suffer recurrent attacks of clotting of small blood vessels, that can cause damage to major organs, including the central nervous system. acute attacks can be treated successfully with infusions of human plasma, and some patients also receive regular plasma therapy for prevention of acute attacks. a small group of patients receive preventive plasma infusions twice or more weekly, indicating a much higher need for plasma than what is otherwise recommended for preventive therapy. do these patients have an ongoing activity of their disease despite a stimulus? or a higher turn-over of transfused adamts13? have these patients developed antibodies against transfused adamts13? are any symptoms correlated with signs of disease activity?

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of congenital ttp * on regular prophylactic plasma treatment: \> once weekly (group 1) or \>1 \<3 times monthly (group 2) * between 18 and 65 years * capable of understanding and complying with the protocol exclusion criteria: * pregnancy * acute bout of ttp requiring daily plasma infusions or -exchange for more than 3 days, within the last 2 weeks before intervention period

Keywords: infusions, intravenous plasma adamts-13 protein, human
adherence to physiotherapy scoliosis specific exercises in adolescents with spine deformity: development of a new questionnaire

Conditions: Adherence, Treatment; Spinal Deformity

Summary: this study aims to develop a new instrument capable of providing an efficient measure of the quality and quantity of adherence to physiotherapy scoliosis specific exercises performed at home by growing patients with spinal deformity undergoing conservative treatment at a specialized institution. the development of a questionnaire in a rasch environment and specifically developed for this population will ensure greater sensitivity and specificity of the questionnaire.


Eligibility criteria:
inclusion criteria: * aged between 10 and 18 years * adolescent idiopathic scoliosis of 10 ° cobb or more * scheuermann's kyphosis or idiopathic hyperkyphosis * prescription of specific exercises exclusion criteria: * positive neurological evaluation
efficacy and safety of colchicine for the prevention of gout flares during the initiation of allopurinol

Conditions: Intercritical Gout

Summary: the purpose of this study is to determine if once-daily treatment with colchicine, compared to placebo, is effective in preventing gout flares in patients who are initiating therapy with allopurinol.


Eligibility criteria:
inclusion criteria: inclusion criteria include, but are not limited to the following: 1. men and postmenopausal women between the ages of 18 and 70 2. meets the ara criteria for classification of acute gout 3. tophi present and/or a history of gout attacks in 2 or 3 joints 4. self-reported history of at least 2 gout flares in the prior 12 months 5. serum uric acid greater than or equal to 7.5 mg/dl at the first visit exclusion criteria: exclusion criteria include, but are not limited to the following: 1. patients with an acute gout flare within 2 weeks prior to the first visit 2. patients with chronic, active gout with at least 1 continuously inflamed joint for at least 4 weeks 3. patients with more than three joints affected by gout 4. history of intolerance or allergy to colchicine or allopurinol 5. use of allopurinol, benzbromarone, febuxostat, probenecid, or sulfinpyrazone less than 3 months prior to entering the study 6. use of colchicine less than 14 days prior to entering the study

Keywords: gout
the effect of distant reiki on pain and holistic well-being

Conditions: Phantom Limb Pain

Summary: phantom limb pain is a condition characterized by painful sensations in the missing part of the amputated limb, which reduces the quality of life of the individual. it has been reported that approximately 85% of patients undergoing amputation experience phantom limb pain, and chronic pain is the most common symptom in individuals who have undergone limb amputation. these problems negatively affect individuals physically, mentally and socially and lead to deterioration of holistic well-being. this study will be examined the effect of distant reiki on pain and holistic well-being of ındividuals with phantom pain after amputation.

phantom limb pain is a condition characterized by painful sensations in the missing part of the amputated limb, which reduces the quality of life of the individual. it has been reported that approximately 85% of patients undergoing amputation experience phantom limb pain, and chronic pain is the most common symptom in individuals who have undergone limb amputation. these problems negatively affect individuals physically, mentally and socially and lead to deterioration of holistic well-being. reiki is one of the holistic health practices that is effective in maintaining the balance between body, mind and spirit, which forms the basis of holistic well-being. reiki, known as an energy-based therapy, helps to rebalance the natural energy flow circulating in the body and to increase the body's self-healing ability, and it prevents or repairs physical, emotional and mental imbalances by regaining the energy we lost in daily life. the purpose of reiki practice is to promote health and well-being by helping to relax and reduce stress.there is no study in the literature examining the effect of reiki application on phantom pain and holistic well-being.this study was planned to examine the effect of remote reiki applied to individuals with post-amputation phantom pain on pain and holistic well-being.it is thought that it will contribute to the literature in terms of being the first research to be done on this subject.

Eligibility criteria:
inclusion criteria: * above 18 years old, * i̇ndividuals with limb loss and phantom pain * no communication problem, * have the physical and cognitive ability to answer the data collection forms, * individuals who have not received body-mind therapy (yoga, reiki, meditation, etc.) exclusion criteria: * individuals who have done reiki therapy before
prp vs ha intra-articular injections in tmds

Conditions: Temporomandibular Joint Disorders; Temporomandibular Joint Pain

Summary: this clinical trial aims to compare the multidirectional mandibular mobility following the treatment of tmj disorders with same-protocol intra-articular injections of prp and ha. it is questioned whether there is direct clinical evidence of the superiority of prp or ha in the injection treatment of tmj disorders.

this study was designed as a two-arm equal-allocation clinical trial with a non-concurrent active treatment control. the study group consisted of consecutive patients receiving prp injections into the tmj cavities. the control group consisted of the same number of patients who received ha according to the same protocol. controls were recruited consecutively, men and women separately, to maintain a consistent male-to-female ratio. the main condition for recruitment was the diagnosis of tmj pain by a specialist in orthodontics or dental prosthetics and, on this basis, a referral for injection treatment. tmj pain was diagnosed under the icop 2020 guidelines. the treatment was performed at the maxillofacial surgery clinic in kielce, poland. the study group received prp from peripheral venous blood of the elbow bend centrifuged at 160 revolutions per minute for 5 minutes with ifuge d06 (neuation technologies pvt. ltd, gujarat, india). the control group received 2% hyaluronic acid synocrom forte (croma-pharma gmbh, leobendorf, austria). in both groups, 0.4 ml of the solution was injected per joint.

Eligibility criteria:
inclusion criteria: * icop 2020 diagnosis of tmj pain; * informed consent to participate in the study; * the possibility of discontinuing the current treatment of the temporomandibular joints; * generally accepted indications for injection therapy. exclusion criteria: * active cancer; * hematopoietic system disease or bleeding diathesis; * temporomandibular joint prosthesis; * temporomandibular joint ankylosis; * skin disease of the preauricular area of the affected side.
a study of cetrelimab in participants with chronic hepatitis b virus infection

Conditions: Hepatitis B, Chronic

Summary: the purpose of the study is to characterize the pharmacokinetic (pk) profile of cetrelimab administered subcutaneous (sc) and optionally intravenous (iv) in chronic hepatitis b (chb) participants.

hepatitis b virus (hbv) is a small deoxyribonucleic acid (dna) virus that infects the liver and can cause either acute (less than 6 months) or chronic (more than 6 months) infection. persistence of hbv infection requires antigen-specific immune tolerance that prevents clearance of infected cells. cetrelimab (jnj-63723283) is a fully human immunoglobulin (ig) g4 kappa monoclonal antibody (mab) that binds to programmed cell death receptor-1 (pd-1) with high affinity and specificity. pd-(l)1 inhibitors could possibly reverse the immune dysfunction from hbv. the study will be conducted in 3 phases: a screening phase (6 weeks), a single dose intervention phase (1 day), and a 24-week follow-up phase. the duration of individual participation will be up to 30 weeks. key safety assessments include monitoring of adverse events (aes), physical examination, vital signs, electrocardiogram (ecgs), injection site reaction (isrs), infusion-related reaction (irrs), and clinical laboratory tests.

Eligibility criteria:
inclusion criteria: * must have chronic hepatitis b virus (hbv) infection documented * participants should be virologically suppressed, hepatitis be antigen (hbeag) status (positive or negative) be on stable nucleotide analog (na) treatment for at least 6 months * must have: a) a liver biopsy result classified as metavir f0-f2 within 2 years prior to screening; b) if a liver biopsy result is not available: fibroscan liver stiffness measurement less than or equal to (\<=) to 9.0 kilopascals (kpa) within 6 months prior to screening or at the time of screening * must be medically stable * must have a body mass index (weight in kilogram \[kg\] divided by the square of height in meters) between 18.0 and 30.0 kilograms per meter square (kg/m\^2), extremes included exclusion criteria * history or evidence of clinical signs or symptoms of hepatic decompensation, including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices * participants with evidence of liver disease of non-hbv etiology. * participants with history or signs of cirrhosis or portal hypertension (nodules, no smooth liver contour, no normal portal vein, spleen size greater than or equal to \[\>=\] 12 centimeters) or signs of hepatocellular carcinoma (hcc) on an abdominal ultrasound performed within 6 months prior to screening or at the time of screening * history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)